HydroGraph partners with Hawkeye Bio and Ease Healthcare on graphene biosensors for lung cancer detection

LEAP is a non-invasive, radiation-free, and highly sensitive blood test designed to detect early signs of lung cancer, even in asymptomatic patients, and across all subtypes. Initially targeting high-risk populations including older smokers, military personnel, firefighters, and first responders, the test has demonstrated a 99.8% negative predictive value, significantly improving early detection outcomes.

Graphene producer HydroGraph has announced a strategic partnership with Hawkeye Bio and Ease Healthcare. Under the new agreement, Ease Healthcare will market the LEAP (Lung Enzyme Activity Profile) early detection test that incorporates HydroGraph’s patented fractal graphene.LEAP is a non-invasive, radiation-free, and highly sensitive blood test designed to detect early signs of lung cancer, even in asymptomatic patients, and across all subtypes. Initially targeting high-risk populations including older smokers, military personnel, firefighters, and first responders, the test has demonstrated a 99.8% negative predictive value, significantly improving early detection outcomes.

Read More Graphene-Info – Graphene industry portal